- Dividend maintained in spite of challenges
- Pharma business to drive growth
Investors rarely respond well to an objectively lacklustre company update. Croda International’s (CRDA) half-year results – which showed substantial declines in both revenue and pre-tax profit – proved to be something of an exception. The company’s shares rose by nearly 5 per cent on the morning the figures were released.